186 related articles for article (PubMed ID: 16773186)
1. Elevated pleural fluid RCAS1 is a diagnostic marker and outcome predictor in lung cancer patients.
Aoe K; Hiraki A; Yamazaki K; Nakamura Y; Murakami T; Maeda T; Nishimura M; Sugi K; Ueoka H
Int J Oncol; 2006 Jul; 29(1):65-72. PubMed ID: 16773186
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
[TBL] [Abstract][Full Text] [Related]
3. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma].
Tokuyama T; Yoneda T; Hamada K; Yoshikawa M; Fu A; Tomoda K; Nakaya M; Narita N; Tamura M; Kitamura K
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jan; 33(1):39-43. PubMed ID: 7699966
[TBL] [Abstract][Full Text] [Related]
5. Soluble receptor-binding cancer antigen expressed on SiSo cells in pleural fluid: a potential diagnostic marker for malignant pleural effusion.
Aoe K; Hiraki A; Maeda T; Murakami T; Yamazaki K; Sugi K; Takeyama H
Chest; 2004 Oct; 126(4):1195-7. PubMed ID: 15486382
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.
Toumbis M; Rasidakis A; Passalidou E; Kalomenidis J; Alchanatis M; Orphanidou D; Jordanoglou J
Anticancer Res; 1996; 16(4A):2101-4. PubMed ID: 8712750
[TBL] [Abstract][Full Text] [Related]
7. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of pleural fluid data in patients with malignant effusion.
Bielsa S; Salud A; Martínez M; Esquerda A; Martín A; Rodríguez-Panadero F; Porcel JM
Eur J Intern Med; 2008 Jul; 19(5):334-9. PubMed ID: 18549935
[TBL] [Abstract][Full Text] [Related]
9. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions.
Bielsa S; Esquerda A; Salud A; Montes A; Arellano E; Rodríguez-Panadero F; Porcel JM
Eur J Intern Med; 2009 Jul; 20(4):383-6. PubMed ID: 19524179
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Dong J; Sun G; Zhu H
Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
[TBL] [Abstract][Full Text] [Related]
11. Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Hsu IL; Su WC; Yan JJ; Chang JM; Lai WW
Lung Cancer; 2009 Sep; 65(3):371-6. PubMed ID: 19157636
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
13. New approaches in the diagnostic procedure of malignant pleural effusions.
Terracciano D; Di Carlo A; Papa P; Cicalese M; Maietta P; Cecere C; Mariano A; Macchia V
Oncol Rep; 2004 Jul; 12(1):79-83. PubMed ID: 15201963
[TBL] [Abstract][Full Text] [Related]
14. [A clinical evaluation of CA 125 levels in serum, ascites and pleural effusion].
Jibiki K; Demura R; Abe Y; Odagiri E; Demura H
Gan No Rinsho; 1987 Nov; 33(14):1756-62. PubMed ID: 3480363
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions.
Duysinx BC; Corhay JL; Hubin L; Nguyen D; Henket M; Louis R
Respir Med; 2008 Dec; 102(12):1708-14. PubMed ID: 18760578
[TBL] [Abstract][Full Text] [Related]
16. Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions.
Porcel JM; Salud A; Vives M; Esquerda A; Rodríguez-Panadero F
Clin Biochem; 2005 Nov; 38(11):1031-3. PubMed ID: 15925354
[TBL] [Abstract][Full Text] [Related]
17. Predictors of mortality within three months in the patients with malignant pleural effusion.
Ozyurtkan MO; Balci AE; Cakmak M
Eur J Intern Med; 2010 Feb; 21(1):30-4. PubMed ID: 20122610
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
Gaspar MJ; De Miguel J; García Díaz JD; Díez M
Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938
[TBL] [Abstract][Full Text] [Related]
19. Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer.
Wu YK; Chen KT; Kuo YB; Huang YS; Chan EC
Cancer Lett; 2009 Jan; 273(2):331-5. PubMed ID: 18824294
[TBL] [Abstract][Full Text] [Related]
20. [Differential prognosis of patients with breast cancer with pleuritis carcinomatosa and with pulmonary lymphangiosis carcinomatosa].
Baur M; Schlappack O; Jakesz R; Dittrich C
Wien Klin Wochenschr; 1992; 104(23):714-6. PubMed ID: 1475980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
